13C-美沙西丁呼气试验在急性肝衰竭及非对乙酰氨基酚急性肝损伤成人中的预后价值
这项前瞻性多中心研究纳入62例成人急性肝衰竭(ALF)或非对乙酰氨基酚急性肝损伤(ALI)患者,评估13C-美沙西丁呼气试验(MBT)对21天无移植生存的预测价值。结果示非存活者第1或2天平均PDR峰值显著低于无移植存活者(2.3%/小时 vs. 9.1%/小时,P<0.0001),MBT的AUROC为0.88(95%CI 0.79-0.97),高于King's College评分(0.70)和MELD评分(0.83)。
要点
- 非存活者第1或2天平均PDR峰值显著低于无移植存活者(2.3%/小时 vs. 9.1%/小时,P<0.0001)。
- MBT预测21天结局的AUROC为0.88(95%CI 0.79-0.97),优于King's College评分(0.70)和MELD评分(0.83)。
- MBT耐受良好,仅报告2例胃肠道不良事件。
核心结论
- 13C-MBT是估测ALF和ALI患者肝脏恢复可能性的有前景工具。
- 利用MBT的PDR峰值数据可能辅助医疗决策,帮助危重ALF和ALI患者避免不必要的移植。
研究设计与样本
- 前瞻性、多中心研究,2016年5月至2019年8月筛查280例,最终纳入62例数据充分的成人患者。
- 中位年龄43岁,79%为白人,76%为ALF,24%为ALI。
- 在研究的第1、2、3、5和7天,使用13C-MBT BreathID设备测定口服13C-美沙西丁溶液后60分钟内呼出13CO2/12CO2比值变化相对于摄入前比值的百分比剂量恢复(PDR)。
主要发现
- 非存活者第1或2天平均PDR峰值显著低于无移植存活者(2.3%/小时 vs. 9.1%/小时;P<0.0001)。
- 连续PDR峰值在非存活者中始终低于存活者(P<0.0001)。
- 13C-MBT在合并队列中的AUROC为0.88(95%CI:0.79-0.97),高于King's College评分(AUROC=0.70)和MELD评分(AUROC=0.83)。
- 13C-MBT耐受良好,仅报告2例胃肠道不良事件。
临床怎么用
- 13C-MBT或可用于估测ALF和ALI患者肝脏恢复可能性,辅助医疗决策。
- PDR峰值数据可能帮助避免危重ALF和ALI患者不必要的移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The 13 C-methacetin breath test (MBT) is a noninvasive, quantitative hepatic metabolic function test. The aim of this prospective, multicenter study was to determine the utility of initial and serial 13 C-MBT in predicting 21-day outcomes in adults with acute liver failure (ALF) and non-acetaminophen acute liver injury (ALI). APPROACH AND RESULTS: The 13 C-MBT BreathID device (Exalenz Biosciences, Ltd.) provided the percent dose recovery (PDR) for a duration of 60 minutes after administration of 13 C-methacetin solution as the change in exhaled 13 CO2 /12 CO2 compared with pre-ingestion ratio on study days 1, 2, 3, 5, and 7. Results were correlated with 21-day transplant-free survival and other prognostic indices. A total of 280 subjects were screened for enrollment between May 2016 and August 2019. Median age of the 62 enrolled patients with adequate data was 43 years, 79% were Caucasian, 76% had ALF with the remaining 24% having ALI. The mean PDR peak on day 1 or day 2 was significantly lower in nonsurvivors compared with transplant-free survivors (2.3%/hour vs. 9.1%/hour; P < 0.0001). In addition, serial PDR peaks were consistently lower in nonsurvivors versus survivors (P < 0.0001). The area under the receiver operating characteristic curve (AUROC) of the 13 C-MBT in the combined cohort was 0.88 (95% CI: 0.79-0.97) and higher than that provided by King's College (AUROC = 0.70) and Model for End-Stage Liver Disease scores (AUROC = 0.83). The 13 C-MBT was well tolerated with only two gastrointestinal adverse events reported. CONCLUSIONS: The 13 C-MBT is a promising tool to estimate the likelihood of hepatic recovery in patients with ALF and ALI. Use of the PDR peak data from the 13 C-MBT point-of-care test may assist with medical decision making and help avoid unnecessary transplantation in critically ill patients with ALF and ALI.
引用
- Fontana RJ, Stravitz RT, Durkalski V, et al. Prognostic Value of the 13 C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury. Hepatology. 2021. PMID: 33660316. doi:10.1002/hep.31783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。